RCS - Diaceutics PLC - Diaceutics launches daily alerts for DXRX platform

DiaceuticsAnnouncement

29/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230829:nRSc5343Ka&default-theme=true

RNS Number : 5343K  Diaceutics PLC  29 August 2023

RNS Reach

29 August 2023

 

 

Diaceutics launches daily alerts for DXRX platform

 

Daily alerts will enable pharma clients to identify patients previously not
receiving the most appropriate treatment due to lack of timely data

 

Diaceutics PLC (https://www.diaceutics.com/) (AIM: DXRX), a leading technology
and solutions provider to the pharmaceutical industry, is pleased to announce
an important and innovative upgrade to its DXRX platform which sees the
Company's DXRX Signal product now providing alerts on a daily basis. This
ground-breaking innovation will provide Diaceutics' customers with even more
timely data to identify patients who would benefit from their therapies and
improve their commercial success. For patients, it means their chances of
receiving the optimal therapy within the window of effectiveness is
significantly improved.

 

DXRX Signal utilizes real-world data collected from a diverse network of over
~500 labs, encompassing academic, community, and commercial facilities. This
comprehensive data pool ensures supply chain reliability and encompasses both
geographical and clinical diversity. For Diaceutics' customers, this
translates into extensive coverage across a spectrum of medical conditions,
including oncology, rare diseases, auto-immune disorders, cardiovascular and
infectious diseases.

 

DXRX Signal has identified over 46,000 patients so far in 2023 for its
biopharma clients.

 

Building upon the foundation of DXRX Signal, Diaceutics has introduced this
pivotal enhancement. These alerts, now available on a daily basis, empower
Diaceutics' customers with even timelier insights as they deploy products to
pinpoint patients and elevate their commercial success. This innovation equips
healthcare professionals with crucial data on a daily basis, and within days
of a positive test result. With increased timely access to diagnostic
information, physicians can be engaged precisely during the treatment decision
window, ensuring the most effective drugs or therapies are offered promptly to
patients.

 

In 2022, the 'Practice Gaps Study' highlighted the existence of seven distinct
clinical practice gaps. These gaps collectively contributed to a concerning
statistic: 64.4% of cancer patients did not receive the appropriate targeted
therapy, of which, 29.2% of patients were lost at the critical treatment
decision juncture of their medical journey. DXRX Signal specifically targets
this cohort of patients, previously not receiving the most appropriate
treatment due to lack of timely data.

 

Available only through the Diaceutics platform, DXRX Signal utilizes our lab
data to identify physicians with a patient who has tested positive for a
specific biomarker of interest, which may be eligible for therapy. This signal
is seamlessly integrated within a customers' operations within as little as 48
hours of the positive test result. From this, they are able to target that
physician with a well-informed engagement before a treatment decision has been
made so that they can offer a more effective drug or therapy sooner; a key
goal for all involved in precision medicine.

 

Jordan Clark, Chief Commercial Officer of Diaceutics plc, commented: "We
recognize the critical importance of engaging physicians during the treatment
decision window. By utilizing DXRX Signal, we empower our clients to
capitalise on this pivotal moment, ultimately reducing patient losses during
this vital stage - the largest 'practice gap.' This enhancement not only
increases awareness and biomarker-precision medicine association but also
ensures patients receive the precise treatments they deserve, fostering
superior clinical outcomes."

 

Peter Keeling, Chief Executive Officer of Diaceutics plc, commented: "We are
breaking new ground with DXRX Signal. This data has simply not been accessible
previously to pharma, which we believe is one of the reasons such a worryingly
high proportion of patients who could benefit from precision medicine are not
receiving it in time. In 2023, we have so far identified over 46,000 patients
for whom a specific medicine could change their clinical outcome and we will
continue to innovate to ensure that that number increases minute by minute,
hour by hour."

 

Enquiries:

 

 

 Diaceutics PLC                                        Tel: +44 (0)28 9040 6500
 Peter Keeling, Chief Executive Officer               investorrelations@diaceutics.com

 Ryan Keeling, Chief Innovation Officer

 Nick Roberts, Chief Financial Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland

 Kate Hanshaw

 Alma PR                                              Tel: +44 (0)20 3405 0205
 Caroline Forde                                       diaceutics@almapr.co.uk
 Matthew Young
 Kinvara Verdon

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharmaceutical and life
science companies with solutions and technology for the commercialisation of
their precision medicines, enabled by our proprietary DXRX platform.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, utilising a global network of affiliate laboratories to deliver
multiple pipelines of real-world healthcare data insights, advisory services
and innovative platform enabled solutions.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFLVTTIDFIV